The exploration of EPI-X4 as a ligand of the tumoral marker CXCR4 allows the exploitation of a novel humanized tool, and it also offers realistic possibilities for the development of a new generation of safe and stable drugs for targeted cancer therapy. This evidence concerns the gene CXCR4 and cancer.